跳至主要内容
临床试验/NCT00490360
NCT00490360已完成2 期

Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head

University of Zurich1 个研究点 分布在 1 个国家目标入组 2,007 人开始时间: 2001年10月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
2,007
试验地点
1
主要终点
Resectability rate > 70% after restaging

研究概览

简要总结

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.

详细描述

Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head. Two cycles of chemotherapy are given on day 1 and 15 each. After restaging excludes disease progression, a standard Whipple procedure is performed.

Staging and restaging procedures include abdominal CT, diagnostic laparoscopy, PET/CT, tumor markers (CEA, CA 19-9) and assessment of the quality of life by the QLQ-30.

  • Trial with medicinal product

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Resectability rate > 70% after restaging

时间窗: 2007

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验

已完成
2 期
Gemcitabine in Combination With Cisplatin as Neoadjuvant NSCLC ChemotherapyCarcinoma, Non-Small-Cell Lung
NCT00191841Eli Lilly and Company50
进行中(未招募)
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-005078-70-ATniversity Medical Center Hamburg-Eppendorf440
进行中(未招募)
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0Level: LLTClassification code 10017620Term: Gallbladder carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-005078-70-ITIVERSITäTKLINIKUM HAMBURG-EPPENDORF781
进行中(未招募)
1 期
Prophylactic combined chemotherapy for patients with cholangiocarcinoma after curative intent of carcinoma resection and muscle invasive gallbladder carcinoma.Cholangiocarcinoma and gallbladder carcinomaMedDRA version: 20.0 Level: LLT Classification code 10017620 Term: Gallbladder carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10008593 Term: Cholangiocarcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-005078-70-DKniversity Medical Center Hamburg-Eppendorf60
招募中
3 期
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial)Biliary tract cancerCholangio/gallblader carcinoma10019815
NL-OMON53034Amsterdam UMC172